HUTCHMED (China) Limited (HCM)
NASDAQ: HCM · Real-Time Price · USD
13.81
+0.04 (0.29%)
Mar 10, 2026, 4:00 PM EDT - Market closed
HUTCHMED (China) Revenue
In the year 2025, HUTCHMED (China) had annual revenue of $548.51M, down -12.96%. HUTCHMED (China) had revenue of $135.42M in the half year ending December 31, 2025, a decrease of -16.54%.
Revenue (ttm)
$548.51M
Revenue Growth
-12.96%
P/S Ratio
4.51
Revenue / Employee
$308,153
Employees
1,780
Market Cap
2.48B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 548.51M | -81.69M | -12.96% |
| Dec 31, 2024 | 630.20M | -207.80M | -24.80% |
| Dec 31, 2023 | 838.00M | 411.59M | 96.52% |
| Dec 31, 2022 | 426.41M | 70.28M | 19.73% |
| Dec 31, 2021 | 356.13M | 128.15M | 56.21% |
| Dec 31, 2020 | 227.98M | 23.09M | 11.27% |
| Dec 31, 2019 | 204.89M | -9.22M | -4.31% |
| Dec 31, 2018 | 214.11M | -27.09M | -11.23% |
| Dec 31, 2017 | 241.20M | 25.12M | 11.63% |
| Dec 31, 2016 | 216.08M | 37.88M | 21.25% |
| Dec 31, 2015 | 178.20M | 90.87M | 104.06% |
| Dec 31, 2014 | 87.33M | 41.36M | 89.97% |
| Dec 31, 2013 | 45.97M | 23.60M | 105.53% |
| Dec 31, 2012 | 22.37M | -142.66M | -86.45% |
| Dec 31, 2011 | 165.03M | 127.17M | 335.88% |
| Dec 31, 2005 | 37.86M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bausch Health Companies | 10.27B |
| Perrigo Company | 4.25B |
| Amneal Pharmaceuticals | 3.02B |
| Phibro Animal Health | 1.46B |
| Prestige Consumer Healthcare | 1.10B |
| ANI Pharmaceuticals | 883.37M |
| BioCryst Pharmaceuticals | 874.84M |
| Supernus Pharmaceuticals | 718.95M |
HCM News
- 1 day ago - Hutchmed (HCM) Withdraws Tazverik from China Amid U.S. Market Recall - GuruFocus
- 1 day ago - HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China - GlobeNewsWire
- 4 days ago - Intended Retirement of Independent Non-executive Director and changes of composition of board committees - GlobeNewsWire
- 5 days ago - HUTCHMED (China) Limited (HCM) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - An Overview of HUTCHMED (China)'s Earnings - Benzinga
- 4 weeks ago - HUTCHMED to Announce 2025 Final Results - GlobeNewsWire
- 5 weeks ago - HUTCHMED (China) Ltd (HCM) Stock Price Down 3.53% on Feb 2 - GuruFocus
- 2 months ago - HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet - GlobeNewsWire